Promisemed Hangzhou Meditech Co (BJSE:920069) ROCE %: 16.43% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BJSE:920069 Promisemed Hangzhou Meditech Co Ltd BJSE:920069
18 GF Score
Price ¥33.28
! 1 Warning Sign
View Full Analysis

What is Promisemed Hangzhou Meditech Co ROCE %?

Promisemed Hangzhou Meditech Co BJSE:920069 18 ROCE % is 16.43% as of Jun. 2026. GuruFocus rates BJSE:920069 with a GF Score™ of 18/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Promisemed Hangzhou Meditech Co's annualized ROCE % for the quarter that ended in Jun. 2026 was 16.43%.

Promisemed Hangzhou Meditech Co  (BJSE:920069) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Promisemed Hangzhou Meditech Co ROCE % Related Terms

Promisemed Hangzhou Meditech Co ROCE % Historical Data

* Premium members only.

The historical data trend for Promisemed Hangzhou Meditech Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Promisemed Hangzhou Meditech Co ROCE % Chart

Promisemed Hangzhou Meditech Co Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROCE %
13.53 10.18 12.99 16.14

Promisemed Hangzhou Meditech Co Quarterly Data
Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 20.21 17.59 -100.68 14.97 16.43
BJSE:920069
18GF Score
Promisemed Hangzhou Meditech Co Ltd BJSE:920069
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Promisemed Hangzhou Meditech Co ROCE % Calculation

Promisemed Hangzhou Meditech Co's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=103.94/( ( (735.592 - 100.147) + (746.396 - 94.169) )/ 2 )
=103.94/( (635.445+652.227)/ 2 )
=103.94/643.836
=16.14 %

Promisemed Hangzhou Meditech Co's ROCE % of for the quarter that ended in Jun. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Jun. 2026 )  (Q: Mar. 2026 )(Q: Jun. 2026 )
=136.62/( ( (918.488 - 82.089) + (912.074 - 85.415) )/ 2 )
=136.62/( ( 836.399 + 826.659 )/ 2 )
=136.62/831.529
=16.43 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 16.43% mean?
Promisemed Hangzhou Meditech Co (BJSE:920069) has a ROCE % of 16.43% as of Jun. 2026.
Is Promisemed Hangzhou Meditech Co's ROCE % too high?
Promisemed Hangzhou Meditech Co's current ROCE % is 16.43%. The Medical Devices & Instruments industry median ROCE % is 2.97. Promisemed Hangzhou Meditech Co's value of 16.43% is 453.2% above this industry median. Overall, Promisemed Hangzhou Meditech Co has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Promisemed Hangzhou Meditech Co's ROCE % compare to ISRG and BDX?
Promisemed Hangzhou Meditech Co's ROCE % of 16.43% can be compared against companies in the Medical Devices & Instruments industry. The industry median ROCE % is 2.97. Promisemed Hangzhou Meditech Co's value of 16.43% is 453.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Devices & Instruments company?
The median ROCE % among Medical Devices & Instruments companies is 2.97, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Promisemed Hangzhou Meditech Co's current ROCE % of 16.43% is 453.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median ROCE % is 2.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Promisemed Hangzhou Meditech Co's current ROCE % is 16.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Promisemed Hangzhou Meditech Co stock overvalued right now?
Promisemed Hangzhou Meditech Co (BJSE:920069) has a current ROCE % of 16.43%. The current ROCE % is 16.43% and 453.2% above the Medical Devices & Instruments industry median of 2.97. Promisemed Hangzhou Meditech Co's overall GF Score™ is 18/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Promisemed Hangzhou Meditech Co (BJSE:920069), the current ROCE % is 16.43% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Promisemed Hangzhou Meditech Co Business Description

Address No. 1388 Cangxing Street, Building 1, Cangqian Subdistrict, Yuhang District, Zhejiang Province, Hangzhou, CHN, 311121
Promisemed Hangzhou Meditech Co Ltd is engaged in the Research, development, production and sales of diabetes care, universal drug delivery and infusion, and minimally invasive interventional medical devices.
18GF Score

Get the complete analysis for BJSE:920069

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥33.28
Price